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Venous neointimal hyperplasia (VNH) causes hemodialysis
vascular access failure. Here we tested whether VNH
formation occurs in part due to local vessel hypoxia caused
by surgical trauma to the vasa vasorum of the outflow vein
at the time of arteriovenous fistula placement. Selective
targeting of the adventitia of the outflow vein at the time of
fistula creation was performed using a lentivirus-delivered
small-hairpin RNA that inhibits VEGF-A expression. This
resulted in significant increase in mean lumen vessel area,
decreased media/adventitia area, and decreased constrictive
remodeling with a significant increase in apoptosis (increase
in caspase 3 activity and TUNEL staining) accompanied with
decreased cellular proliferation and hypoxia-inducible factor-
1a at the outflow vein. There was significant decrease in cells
staining positive for a-smooth muscle actin (a myofibroblast
marker) and VEGFR-1 expression with a decrease in MMP-2
and MMP-9. These results were confirmed in animals that
were treated with humanized monoclonal antibody to
VEGF-A with similar results. Since hypoxia can cause
fibroblast to differentiate into myofibroblasts, we silenced
VEGF-A gene expression in fibroblasts and subjected them to
hypoxia. This decreased myofibroblast production, cellular
proliferation, cell invasion, MMP-2 activity, and increased
caspase 3. Thus, VEGF-A reduction at the time of
arteriovenous fistula placement results in increased positive
vascular remodeling.
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More than 400,000 patients have end-stage renal disease and
require chronic hemodialysis in the United States.1 Vascular
access through an arteriovenous fistula (AVF) is required for
the optimal hemodialysis and clearance of uremic toxins. AVF
failure occurs frequently because of venous stenosis formation,
and the patency of AVFs at 1 year is estimated to be only 62%.2
Over a billion dollars are spent annually to maintain the
function of hemodialysis AVFs and grafts.1 Angioplasty is the
current treatment for treating venous stenosis formation, and
noninvasive treatments that could reduce AVF stenosis would
be advantageous to end-stage renal disease patients.
Venous neointimal hyperplasia (VNH) causes venous
stenosis formation to occur in AVFs.3 When specimens
removed from patients with failed AVFs are examined using
histologic techniques, changes in angiogenesis are observed
within the neointima and adventitia of the vessel. This is
often accompanied with increased proliferation of cells that
are a-smooth muscle actin (a-SMA) positive located within
the neointima.4–6 There are emerging experimental data
demonstrating that adventitial and medial cells, which are
hypothesized to be fibroblasts, will convert to myofibroblasts
(a-SMA-positive cells) and thus contribute to the formation
of VNH.7–10 In vitro studies indicate that hypoxia causes
increased differentiation of fibroblasts to myofibroblasts,
whereas increased expression of hypoxia-inducible factor-1a
(HIF-1a) has been observed in vivo in both animal
models of hemodialysis AVF and graft failure, as well as in
specimens removed from patients with hemodialysis AVF
or graft failure.7,11–14 One plausible explanation for these
observations is that the vasa vasorum supplying the vessel
wall becomes disrupted after the surgical placement of the
AVF. Taken collectively, these observations suggest that
hypoxia-driven angiogenic stimuli enhance matrix deposi-
tion while facilitating the conversion of adventitial fibroblasts
to myofibroblasts.4 Therefore, a therapy aimed at reducing
hypoxia-driven VNH would be useful in reducing stenosis
in AVFs. An ideal therapy to reduce venous stenosis forma-
tion would be one that can be delivered selectively to the
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adventitia of the vessel wall where it might target the resident
fibroblasts. This directed approach to therapy might have
several advantages over systemically delivered therapies
because of higher local concentrations of the drug owing to
direct delivery and reduced clearance by other organs, lower
systemic side effects, and a reduced chance for nontarget
delivery to other vessels or organs.
Vascular endothelial growth factor-A (VEGF-A) is one of
the most potent angiogenic factors, and its action is mediated
through its two receptors: VEGFR-1 (fms-related tyrosine
kinase-1 (Flt-1)) and VEGFR-2 (fetal liver kinase-2 (Flk-2)).
VEGF-A is important in vascular remodeling and it
has been shown to be involved in the pathogenesis of
arterial stenosis, vein bypass grafts, and VNH associated
with hemodialysis vascular access.6,15–22 Previous work
from our and other laboratories has demonstrated that
there is increased expression of VEGF-A, VEGFR-1, and
VEGFR-2 at the site of venous stenosis in murine and
porcine models of hemodialysis AVF and graft failure. Recent
work from our laboratory has shown that simvastatin
treatment before the placement of AVF reduces VNH
formation in a murine model of chronic kidney disease
with AVF by decreasing VEGF-A and matrix metallo-
proteinase (MMP-9).10 This study did not determine the
mechanism by which VEGF-A has a role in VNH formation,
as simvastatin has been implicated in reducing many different
cytokines.13,14,23
Experiments outlined in this study were performed in a
murine model of chronic kidney disease with AVF to test the
hypothesis that reduction of VEGF-A gene expression by
adventitial delivery to the outflow vein of the AVF at the time
of placement would lead to a reduction in several important
downstream matrix regulating genes such as MMP-2 and
MMP-9, and thereby reduces VNH and abnormal vascular
remodeling. Gene expression for VEGF-A was reduced by
adventitial delivery of a small hairpin RNA (shRNA) that
inhibits VEGF-A expression. Gene, protein expression, and
histomorphometric analyses were performed at the outflow
vein after administration of anti-VEGF-A RNA therapy.
We determined whether Avastin, a humanized monoclonal
antibody to VEGF-A (Bevacizumab, Genentech, San Fran-
cisco, CA), would decrease VNH formation. Finally, we
investigated whether VEGF-A expression induced by hypoxia
resulted in myofibroblast formation by silencing VEGF-A
gene expression in fibroblasts and subjecting them to hypoxia
for different time periods, and subsequently determined the
rates of protein expression, cell proliferation, and migration.
RESULTS
Surgical outcomes
A total of 204 male C57BL/6 mice weighing 25–30 g underwent
right nephrectomy and left upper pole occlusion surgery, as
described previously.10 One mouse was used to perform micro-
computed tomography analysis to evaluate the vasa vasorum.
In all, 7 mice died after nephrectomy, 4 after AVF fistula
placement, and 16 had significant arterial thickening and
inflammation such that a new AV fistula could not be placed.
A total of 140 mice underwent placement of an AVF to
connect the right carotid artery to the ipsilateral jugular
vein.10 Next, either 1106 particle-forming units (PFU) of
lentivirus (LV)-shRNA-VEGF-A (LV, n¼ 72) or scrambled-
shRNA-VEGF-A (control (C), n¼ 68) were injected into the
adventitia of the outflow vein where the stenosis forms in this
model.23,24 Animals were killed for gene expression, protein,
or histologic analyses at days 3, 7 14, 21, and 28 after AVF
placement. At the time of killing, the fistula was evaluated
for patency. The fistula was considered to be patent if, when
the outflow vein was compressed, it became dilated under
visual inspection. A separate group of 36 animals underwent
treatment with Avastin (5mg/kg) or immunoglobulin G
(IgG) isotype–matched antibody in equal volume of phos-
phate-buffered saline (PBS) administered intraperitoneally
every other day, which was started 1 week before fistula
placement and continued up to the time of killing. Animals
were killed on day 7 for gene expression of VEGF-A and on
days 14 and 28 after AVF placement for histomorphometric
analysis.
Figure 1 | Vascular endothelial growth factor-A (VEGF-A) expression is reduced in lentivirus (LV)–small hairpin RNA (shRNA)-VEGF-A-
transduced and Avastin-treated vessels with decreased CD31 staining. (a, first to third columns) In situ hybridization of mRNA for VEGF-A
in the LV-transduced vessels when compared with scrambled-shRNA-VEGF-A (control (C)) vessels, with arrows on cells positive for VEGF-A
mRNA expression (brown). By day 3 (D3), there was a reduction of mRNA for VEGF-A being localized to the media and adventitia and by day 7
(D7), it was localized to the media and intima. In contrast, the vessels transduced with C shRNA showed increased mRNA expression of VEGF-A
in the adventitia and media by day 3, and in the media and intima by day 7. (b) Pooled data for the in situ transcript levels of VEGF-A in the
outflow vein of the LV-transduced vessels that was significantly reduced when compared with C vessels at day 7 (Po0.0001). (c) Upper panel
shows the representative real-time PCR (RT-PCR) blots of the VEGF-A with 18S gene for loading with pooled data from the mean gene
expression of VEGF-A using RT-PCR analysis. This demonstrates that there is significant reduction in the mean VEGF-A expression in the
LV-transduced vessels when compared with C vessels at day 7 (Po0.0001). (d) Representative sections from VEGF-A staining at the venous
stenosis of the LV and C-transduced vessels or Avastin-treated or immunoglobulin G (IgG) controls at days 14 and 28. At day 14, there is a
significant reduction in the mean VEGF-A staining in the LV-transduced vessels and Avastin-treated vessels when compared with controls
(Po0.0001). (e) Representative sections from CD31 staining at the venous stenosis of the LV and C-transduced vessels or Avastin-treated
vessels or IgG controls at days 14 and 28. Cells staining brown are positive for CD-31. All are original magnification 40. Bar¼ 200 mm.
*Indicates the lumen. Qualitatively, in the C tissue, when compared with the LV-transduced vessels, there is increased CD31 staining localized
to the neointima/media junction by days 14 to 28 in the control tissue. Similar results in the IgG control tissues when compared with Avastin-
treated vessels. (b–d) Each bar shows mean±s.e.m. of 4–6 animals per group. Two-way analysis of variance (ANOVA) followed by Student’s
t-test with post hoc Bonferroni’s correction was performed. Significant difference from control value is indicated by #Po0.0001.
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Serum blood urea nitrogen (BUN) and creatinine after
nephrectomy
In this model, we observed elevated creatinine and BUN levels
similar to what is observed in the typical clinical scenario.
The mean BUN and creatinine at baseline was 28±5 and
0.26±0.1mg/dl, respectively. The mean BUN increased
significantly at 5, 6, and 8 weeks after nephrectomy when
compared with baseline (Po0.05). In addition, there was no
difference in the mean BUN and creatinine between the
Avastin-treated or control animals.
Adventitial transduction of LV-shRNA-VEGF-A to the outflow
vein reduces gene expression of VEGF-A at days 3 and 7 and
VEGF-A staining until day 14
The efficacy of reducing VEGF-A gene expression in vitro was
first determined in AKR-2B (murine fibroblast cell line) cells,
which were transduced with either LV-shRNA-VEGF-A (LV)
or scrambled shRNA-VEGF-A (C, control). Real-time PCR
(RT-PCR) (Supplementary Figure S1A online) and western
blot analyses (Supplementary Figure S1B online) demon-
strated a greater than twofold decrease in VEGF-A expression
in the LV-shRNA-VEGF-A-transduced cells when compared
with controls. To ascertain whether similar findings are
present in vivo, experiments were designed and performed to
determine the distribution of the LV in the vasculature after
delivery to the vessel wall.
The amount of reduction and localization of VEGF-A gene
expression was determined in vivo using in situ hybridization
for VEGF-A. By day 3, there was a reduction of mRNA for
VEGF-A (brown staining in cells) being localized to the media
and adventitia and, by day 7, it was localized to the media
and intima (Figure 1a, first to third columns). In contrast, the
vessels transduced with control shRNA showed increased
mRNA expression of VEGF-A in the adventitia and media by
day 3, and in the media and intima by day 7. Semiquantitative
analysis of the in situ hybridization was performed, and it
confirmed a significant reduction in the mRNA levels in the
LV-shRNA-VEGF-A-transduced vessels when compared with
control vessels by day 7 (24.5±3.3 vs. 65.3±6, respectively,
Po0.0001, average reduction: 62%, Figure 1b). Our next set
of studies used RT-PCR analysis for VEGF-A on sections
removed from the outflow vein at days 7, 14, and 28 after
lentiviral transduction. By day 7, the mean gene expression of
VEGF-A at the LV-shRNA-VEGF-A-transduced vessels was
significantly lower than the control vessels (1.31±0.17 vs.
1.96±0.15, respectively, Po0.0001, average reduction: 44%,
Figure 1c), and by days 14 and 28 there was no difference in
expression between the two groups (P¼not significant (NS)).
Next, we determined the gene expression of VEGF-A in the
Avastin-treated vessels when compared with controls at day 7.
By day 7, we observed a significant reduction in VEGF-A
expression in the Avastin-treated vessels when compared with
controls (0.34±0.05 vs. 0.67±0.12, respectively; Po0.05,
average reduction: 49%).
The decrease in expression of the protein lags behind the
decrease in gene expression. We determined the expression of
VEGF-A after silencing using immunohistochemistry at days
14, 21, and 28 after LV silencing of VEGF-A. We observed a
significant reduction in the average VEGF-A staining at day 14
in the LV-VEGF-A-transduced vessels when compared with
controls (22.5±2.7 vs. 40.4±1.4, respectively, Po0.0001,
average reduction: 44%, Figure 1d). There was no difference
at days 21 and 28 between the two groups. Finally, we
determined the VEGF-A expression in the Avastin-treated
vessels when compared with controls and observed similar
findings. By day 14, there was a significant reduction in the
average VEGF-A staining in the Avastin-treated vessels when
compared with controls (3.8±0.5 vs. 16.8±1.8, respectively,
Po0.0001, average reduction: 77%, Figure 1d).
VEGF-A is responsible for angiogenesis, and it was assessed
using CD31 staining. We observed qualitatively in the control
vessels that, when compared with the LV-shRNA-VEGF-A-
transduced vessels, there is increased CD31 staining with
microvessel formation localized to the adventitia/media junc-
tion by days 14 to 28, which was associated with a reduced
luminal vessel area (Figure 1e). Similar findings were observed
in the Avastin-treated vessels when compared with controls.
Collectively, these results indicate that the reduction in
mRNA was reduced in adventitia and media at day 3, and by
day 7 it was in the media and intima following a ‘top-down
effect.’ Taken collectively, these results indicate that mRNA
levels of VEGF-A can be reduced at the outflow vein using
adventitial delivery of LV-shRNA-VEGF-A, and the reduction
in VEGF-A mRNA signal lasts for 1 week after delivery
(Table 1). Moreover, VEGF-A staining shows a reduction in
the VEGF-A protein expression until 2 weeks after both
lentiviral delivery and Avastin treatment. There was a
decrease in the CD31 staining in both the LV-shRNA-
VEGF-A-transduced and Avastin-treated vessels when com-
pared with controls.
Adventitial transduction of LV-shRNA-VEGF-A to the outflow
vein promotes positive vascular remodeling with a decrease
in constrictive remodeling
We hypothesized that reducing mRNA levels of VEGF-A by
adventitial transduction of LV-shRNA-VEGF-A to the out-
flow vein or systemic delivery of Avastin would result in
positive vascular remodeling at the outflow vein (Figure 2).
We used hematoxylin and eosin staining (Figure 2a, first
column) and picrosirius red staining (Figure 2a, second
column) to assess the histomorphometric remodeling. A
representative hematoxylin and eosin stain is shown from
day 14. At days 14–28, there was a significant increase in the
average lumen area of the outflow vein of the LV-shRNA-
VEGF-A-transduced vessels when compared with the control
vessels (Po0.001 for days 14, 21, and 28, average increase:
175–290%, Figure 2b). In the Avastin-treated vessels, we
observed a significant increase in the average lumen vessel
area when compared with controls (Po0.01 for day 14,
average increase: 227%), with no difference by day 28.
Adventitial remodeling has been seen in experimental
models of venous neointimal hyperplasia associated with
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Figure 2 | Hematoxylin and eosin (H&E) and picrosirius red staining of the lentivirus (LV)–small hairpin RNA (shRNA)–vascular
endothelial growth factor-A (VEGF-A)–transduced and Avastin-treated vessels have increased lumen vessel area with decreased media
and adventitia area and collagen expression. (a, first column) Representative sections after H&E at the venous stenosis of the LV-shRNA-
VEGF-A (LV) and scrambled-VEGF-A (control (C))–transduced vessels or Avastin-treated vessels or immunoglobulin G (IgG) controls at day 14
showing increase in lumen vessel area. (a, second column) Representative polarized light microscopy of picrosirius red–stained venous stenosis
showing decreased fibrosis (collagen fibers are bright yellow) of the LV and C-transduced vessels and Avastin-treated vessels and controls.
Qualitatively, there is a reduction in collagen staining by Sirius red by days 3–21. *Indicates the lumen. Bar¼ 200 mm. Pooled data for mean
lumen vessel area LV and C groups and Avastin-treated and control vessels are shown in b. There is a significant increase in the mean lumen
vessel area in the LV-transduced vessels when compared with C vessels for days 14–28 (Po0.001 for all). By day 14, there was a significant
increase in the mean lumen vessel area in the Avastin-treated vessels when compared with IgG controls (Po0.001). Pooled data for mean
media and adventitia area in LV and C groups and Avastin and control groups are shown in c. There is a significant decrease in the mean media
and adventitia area in the LV-transduced vessels when compared with C vessels for day 14 (Po0.01). By day 28, there is a significant reduction
in the mean media and adventitia area in the Avastin-treated vessels when compared with controls (Po0.001). (d) Kaplan–Meier estimates for
LV-transduced vessels (red) when compared with C vessels (blue). There is improved patency in the LV-transduced vessels (red) when
compared with C vessels (Log-rank test: Po0.05). (b, c) Each bar shows mean±s.e.m. of 4–6 animals per group. Two-way analysis of variance
(ANOVA) followed by Student’s t-test with post hoc Bonferroni’s correction was performed. Significant difference from control value is indicated
by **Po0.001.
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hemodialysis vascular access.7–9 We determined the area of
the media and adventitia. By day 14, we observed a signi-
ficant reduction in the average area of the media and
adventitia of the LV-transduced vessels when compared with
controls (Po0.01 for day 14, average decrease: 47%,
Figure 2c), with gradual increase by days 21 and 28. In the
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Figure 3 | (a) Representative sections from TdT-mediated dNTP nick end labeling (TUNEL) staining at the venous stenosis of the LV-shRNA-
VEGF-A (LV) with scrambled-VEGF-A (control (C))–transduced control vessels or Avastin-treated with immunoglobulin G (IgG) controls at days 14
and 28. Nuclei staining brown are positive for TUNEL. Negative control is shown where the recombinant terminal deoxynucleotidyl transferase
enzyme was omitted. All are original magnification 40. Bar¼ 200 mm. *Indicates the lumen. Pooled data for LV- and C-transduced vessels or
Avastin-treated or IgG controls are shown in b. This demonstrates a significant increase in the mean TUNEL index at day 14 (Po0.0001) in the
LV group when compared with C group. Similar results are seen in Avastin-treated vessels when compared with IgG controls at day 14
(Po0.0001). Pooled data for the LV- and C-transduced vessels for caspase 3 activity at days 3 (D3), 7 (D7), and 14 (D14) is shown in c. This
demonstrates a significant increase in the mean caspase 3 activities at days 3 to 14 (all Po0.001). Each bar shows mean±s.e.m. of 3–6 animals
per group (b, c). Two-way analysis of variance (ANOVA) followed by Student’s t-test with post hoc Bonferroni’s correction was performed.
Significant difference from control value is indicated by **Po0.001 and #Po0.0001.
Figure 4 | Cellular proliferation, matrix metalloproteinase 2 (MMP-2), and matrix metalloproteinase 9 (MMP-9) are decreased in
lentivirus (LV)–small hairpin RNA (shRNA)–vascular endothelial growth factor-A (VEGF-A)–transduced vessels. (a, upper panel)
Representative sections after Ki-67 staining at the venous stenosis of the LV-shRNA-VEGF-A (LV) and scrambled shRNA (control (C)) or Avastin-
treated vessels or immunoglobulin G (IgG) controls at days 14 (D14) and 28 (D28). Nuclei staining brown are positive for Ki-67. IgG antibody
staining was performed to serve as negative controls. *Indicates the lumen. All are original magnification 40. Bar¼ 200 mm. Pooled data for
the LV and C groups or Avastin-treated vessels or IgG controls are shown in the lower panel. This demonstrates a significant decrease in the
mean Ki-67 index in the LV-transduced vessels when compared with the C vessels at day 14 (Po0.01). Similar results are seen with Avastin-
treated vessels when compared with controls at day 14 (Po0.01). Significant difference from control value is indicated by **Po0.001. Each bar
shows mean±s.e.m. of four animals per group. Pooled data for real-time PCR (RT-PCR) analysis of (b) MMP-2 and (c) MMP-9 expression after
transduction with either LV or C are shown. This demonstrates a significant reduction in the average amount of (b) MMP-2 and (c) MMP-9 in the
LV-transduced vessels when compared with C vessels at day 7 (Po0.0001) with a significant increase in MMP-2 by day 28 (Po0.01). Significant
difference from control value is indicated by *Po0.01 and #Po0.0001. (b, c) Each bar shows mean±s.e.m. of four animals per group. A
representative zymogram for (d) MMP-2 and (e) MMP-9 is shown in the upper panel and the pooled data in the lower panels. By zymography,
(d) pro-MMP-2 expression was significantly decreased in the LV-transduced vessels when compared with C vessels at day 7 (Po0.0001), and by
day 14 both pro and active MMP-2 were significantly decreased (both Po0.0001). By zymography, (e) active-MMP-9 expression was significantly
decreased in the LV-transduced vessels when compared with C vessels at day 14 (Po0.001). (d, e) Each bar shows mean±s.e.m. of 3–6 animals
per group. Two-way analysis of variance (ANOVA) followed by Student’s t-test with post hoc Bonferroni’s correction was performed. Significant
difference from control value is indicated by *Po0.01, **Po0.001, or #Po0.0001.
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Avastin-treated vessels, when compared with controls, there
was a trend to a significant decrease in the average area of the
media and adventitia by day 28 (Po0.001, average decrease:
89%). Interestingly, we did not observe a difference in the
average area of the neointima of either treatment (lentiviral
VEGF-A or Avastin) at any time point, suggesting that the
positive remodeling may be related to the favorable adventitial
and medial remodeling, possibly because of a decrease in the
migration of fibroblasts and smooth muscle cells.
We next determined whether the increase in positive
vascular remodeling was due to a decrease in the collagen 1
and 3 content using picrosirius staining. Yellow color is positive
for collagen 1 or 3 staining (Figure 2a and Supplementary
Figure S2 online). As shown, picrosirius staining was decreased
at days 3, 7, 14, and 21, with recovery by day 28. We also
observed at days 3 and 7 that there was a reduction of the
collagen expression in the adventitia and media with expression
of collagen localized in the intimal area, which persisted at days
14 and 21 (Supplementary Figure S2 online).
Patency of the LV-shRNA-VEGF-A and control
shRNA–transfected vessels at days 3, 7, 14, and 28
Patency of the fistula was determined visually by occluding
the outflow vein before harvesting the tissue. In a patent
fistula, occluding the outflow vein would allow the fistula to
dilate, whereas an occluded fistula would not dilate. This was
performed several times to be certain that the fistula was
occluded or patent. A Kaplan–Meier estimate was performed
for the LV-shRNA-VEGF-A-transduced vessels compared
with controls, as shown in Figure 2d. This showed a signi-
ficant difference in the patency between the LV-shRNA-
VEGF-A-transduced vessels when compared with controls
(Log-rank test: Po0.05).
Adventitial transduction of LV-shRNA-VEGF-A to the outflow
vein increases apoptosis at day 14
Current literature suggests that VEGF-A is needed for
maintaining cellular homeostasis, and therefore we hypothe-
sized that decreasing VEGF-A would result in increased
apoptosis.25 Apoptosis was first assessed using TUNEL
(TdT-mediated dNTP nick end labeling) staining performed
on sections removed after transduction with either LV-shRNA-
VEGF-A or control shRNA (Figure 3, upper panel). By day 14,
the average TUNEL index (number of TUNEL-positive cells
(brown)/total number of cells100) at the outflow vein of the
LV-shRNA-VEGF-A group was significantly higher than the
control group (40.4±1.4 vs. 20.6±2.9, respectively, average
increase: 196%, Po0.0001, Figure 3, lower panel), with no
significant differences by days 21 and 28. Similar observations
were made in the Avastin-treated vessels when compared with
controls. By day 14, there was a significant increase in the
TUNEL index in the Avastin-treated vessels when compared
with controls (3.8±0.5 vs. 16.8±1.8, respectively, average
increase: 442%, Po0.0001, Figure 3, lower panel).
Caspase 3 is an effector of apoptosis. We hypothesized that
increased caspase 3 activity would be present in sections
removed from the outflow vein after transduction with either
LV-shRNA-VEGF-A or control shRNA. By days 3–14, the
average caspase 3 activity was significantly higher in the
LV-shRNA-VEGF-A-transduced vessels when compared with
controls (average increase: 281% at day 3, 368% at day 7, and
365% at day 14, all Po0.001, Figure 3b). Overall, these results
indicate that adventitial delivery of LV-shRNA-VEGF-A results
in a significant increase in caspase 3 activity with accom-
panying increased TUNEL index at the outflow vein,
suggesting that there is increased cell death in LV-shRNA-
VEGF-A-transduced vessels when compared with controls
(Table 1). Similar findings were observed in Avastin-treated
vessels when compared with controls.
Adventitial transduction of LV-shRNA-VEGF-A to the outflow
vein decreases cellular proliferation
VEGF-A is needed for cells to proliferate, and we determined
cell proliferation by performing Ki-67 staining on sections
from the outflow vein after transduction with either
LV-shRNA-VEGF-A or control shRNA (Figure 4a, upper
panel). The average Ki-67 index (number of Ki-67-positive
cells (brown)/total number of cells100) in the LV-shRNA-
VEGF-A group was significantly lower than the control
group by day 14 (7.9±1 vs. 24.6±2.9, respectively, average
reduction: 68%, Po0.01, Figure 4a, lower panel) and by day
21 (25.5±1.3 vs. 37.2±2.3, respectively, average reduction:
35%, Po0.01). In the Avastin-treated vessels when compared
with controls, similar findings were observed at day 14
(9.6±0.8 vs. 31.7±6.1, respectively, average reduction: 70%,
Table 1 | Synopsis of major findings
Day 7 Day 14 Day 21 Day 28
VEGF-A k NC NC
LVA m m m
CD31 k k k
Sirius red k k k NC
TUNEL m NC NC
Caspase 3 m m
Ki-67 k k NC
RT-PCR
MMP-2 k NC m
Pro-MMP-2 k k
Active-MMP-2 NC k
RT-PCR
MMP-9 k NC NC
MMP-9 NC k
a-SMA NC k k
VEGFR-1 k NC NC
HIF-1a NC k
VEGF-A staining k k
Abbreviations: HIF-1a, hypoxia-inducible factor-1a; LVA, lumen vessel area; MMP-2,
matrix metalloproteinase 2; MMP-9, matrix metalloproteinase 9; NC, no change;
RT-PCR, real-time PCR; a-SMA, a-smooth muscle actin; TUNEL, TdT-mediated dNTP
nick end labeling; VEGF-A, vascular endothelial growth factor-A; VEGFR-1, vascular
endothelial growth factor receptor 1.
NC is no change between the lentivirus (LV)–small hairpin RNA (shRNA)–VEGF-A-
transduced specimens and controls.
The symbol ‘m’ indicates significant increase between the LV-shRNA-VEGF-A-
transduced specimens and controls.
The symbol ‘k’ indicates significant decrease between the LV-shRNA-VEGF-A-
transduced specimens and controls.
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Po0.01). In both experimental groups, by day 28, there
was no difference between LV-shRNA-VEGF-A or Avastin
and controls. Overall, these results indicate that cellular
proliferation in the scrambled group is increasing with the
length of time of fistula and decreasing in the LV-shRNA-
VEGF-A group with reduction in both LV-shRNA-VEGF-A-
and Avastin-treated vessels (Table 1).
Adventitial transduction of LV-shRNA-VEGF-A to the outflow
vein reduces the expression of MMP-2 and MMP-9 at the
outflow vein
Several studies have shown that there is increased expression
of MMP-2 and MMP-9 in animal models of hemodialysis
AVF and graft failure, as well as in clinical samples.7,11–14
MMP-2 and MMP-9 gene products are thought to be
responsible for cellular proliferation and cell migration,
resulting in VNH formation.7,11–14 To test this hypothesis, we
designed a set of experiments to ascertain whether reducing
VEGF-A expression would lead to a reduction in MMP-2
and MMP-9 expression.26 Gene expression of MMP-2 and
MMP-9 was determined by RT-PCR analysis on specimens
removed from the outflow vein transduced with either
LV-shRNA-VEGF-A or control shRNA. By day 7, the average
gene expression of both MMP-2 and MMP-9 was significantly
lower in the LV-shRNA-VEGF-A-transduced vessels when
compared with control shRNA (MMP-2: 2.04±0.23 vs.
2.87±0.25, respectively, average reduction: 29%, Po0.0001,
Figure 4b and MMP-9: 0.98±0.13 vs. 2.63±0.17, respec-
tively, average reduction: 63%, Po0.0001, Figure 4c). By day
14, there was no difference in the mean gene expression of
MMP-2 andMMP-9 between both groups (P¼NS); however,
by day 28, there was a significant increase in MMP-2
expression at the LV-shRNA-transduced vessels when com-
pared with controls (0.96±0.3 vs. 0.39±0.13, respectively,
average increase: 246%, Po0.01).
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Figure 5 | Smooth muscle cell index and vascular endothelial growth factor receptor 1 (VEGFR-1) expression are reduced in lentivirus
(LV)–small hairpin RNA (shRNA)–vascular endothelial growth factor-A (VEGF-A)–transduced vessels. (a, upper panel) Representative
sections after a-smooth muscle actin (a-SMA) staining at the venous stenosis of the LV-shRNA-VEGF-A (LV) and scrambled shRNA (control (C))
and Avastin treated with control vessels at days 14 and 28. Cells staining brown are positive for a-SMA. immunoglobulin G (IgG) antibody
staining was performed to serve as negative control. *Indicates the lumen. All are original magnification 40. Bar¼ 200mm. Pooled data for the
LV and C groups and Avastin-treated and control vessels are shown in a (lower panel). This demonstrates a significant reduction in the average
a-SMA index in LV-transduced vessels when compared with C vessels by day 21 (Po0.001) and day 28 (Po0.01). There is also a significant
decrease in the average a-SMA index in Avastin-treated vessels when compared with controls by day 14 (Po0.001). (c) Pooled data from RT-
PCR analysis for VEGFR-1 expression after transduction from the LV and C groups. A typical blot is shown in the upper panel and the pooled
data in the lower panel (c). This demonstrates a significant reduction in the mean VEGFR-1 expression in the LV-transduced vessels when
compared with C vessels at day 7 (Po0.001). (b, c) Each bar shows mean±s.e.m. of 4–6 animals per group. Two-way analysis of variance
(ANOVA) followed by Student’s t-test with post hoc Bonferroni’s correction was performed. Significant difference from control value is indicated
by *Po0.01, **Po0.001, or #Po0.0001.
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Because the translation of the protein lags behind the gene
changes, we assessed the protein activity of MMP-2 and
MMP-9 using zymography performed on the outflow
vein transduced with either LV-shRNA-VEGF-A or control
shRNA at days 7 and 14. By day 7, the average pro-MMP-2
activity was significantly lower in the LV-shRNA-VEGF-A-
transduced vessels when compared with control vessels
(4,309,376±150,167 vs. 5,788,726±12,611, respectively,
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Figure 6 | There is decreased hypoxia-inducible factor-1a (HIF-1a) expression and staining in lentivirus (LV)–small hairpin RNA
(shRNA)–vascular endothelial growth factor-A (VEGF-A)–transduced and Avastin-treated vessels. (a) Real-time PCR (RT- PCR) analysis for
HIF-1a expression after transduction with LV and control shRNA (C). A typical blot is shown in the upper panel and the pooled data in the lower
panel. This demonstrates a significant reduction in average HIF-1a expression in the LV-transduced vessels when compared with C vessels at
days 7 (D7; Po0.001) and 14 (D14; Po0.01). (b) Representative sections after HIF-1a staining at the venous stenosis of the LV-shRNA-VEGF-A
(LV) and C and Avastin- and immunoglobulin G (IgG)–treated vessels at day 14 and day 28. Brown-staining cells are positive for HIF-1a. IgG
antibody staining was performed to serve as negative control. *Indicates the lumen. All are original magnification 40. Bar¼ 200 mm. Pooled
data for the LV-transduced and C vessels and Avastin-treated and control vessels are shown in b. This demonstrates a significant reduction in
the average HIF-1a index in the LV-transduced vessels when compared with C vessels at days 14 (Po0.001) and 21 (Po0.01). There is a
significant reduction in the average HIF-1a index in the LV-transduced vessels when compared with C vessels at days 14 (Po0.001) and 21
(Po0.01). There is no difference in the Avastin-treated vessels compared with controls at either time point. Each bar shows mean±s.e.m. of 4–6
animals per group. Two-way analysis of variance (ANOVA) followed by Student’s t-test with post hoc Bonferroni’s correction was performed.
Significant difference from control value is indicated by #Po0.001.
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average reduction: 26%, Po0.0001, Figure 4d), and by day 14
both pro and active MMP-2 were significantly lower in the
LV-shRNA-VEGF-A-treated vessels when compared with
controls (pro-MMP-2: 3,124,526±122,611 vs. 2,056,144±
150,167, respectively, average reduction: 52%, Po0.0001,
active MMP-2: 2,056,149±150,167 vs. 4,309,376±150,168,
respectively, average reduction: 52%, Po0.0001). By day 14,
the average active MMP-9 activity was significantly lower in
the LV-shRNA-VEGF-A-transduced vessels when compared
with control vessels (2,542,569.5±183,929 vs. 3,424,355±
150,178, respectively, average reduction: 26%, Po0.001,
Figure 4e) (Table 1).
Adventitial transduction of LV-shRNA-VEGF-A to the outflow
vein decreases a-SMA expression
The majority of the cells comprising VNH are positive for
a-SMA. Outflow sections from LV-shRNA-VEGF-A and control
groups were stained for a-SMA (Figure 5a). The average SMA
index (number of SMA-positive cells (brown)/total number of
cells100) at the outflow vein of the LV-shRNA-VEGF-A-
transduced vessels was significantly lower than the control group
by day 21 (36.9±2.3 vs. 63.3±5.8 respectively, average
reduction: 42%, Po0.001, Figure 5b) and day 28 (39.8±6.9
vs. 65.3±6.9, respectively, average reduction: 37%, Po0.01). We
performed vimentin staining and observed no difference
between the two groups (Supplementary Figure S3 online). By
day 14, there was a significant reduction in the SMA index in the
Avastin-treated vessels when compared with controls (32.8±2.1
vs. 53.1±4.1 respectively, average reduction: 38%, Po0.001).
Smooth muscle cells express VEGFR-1. Smooth muscle
cell expression was performed using RT-PCR analysis for
VEGFR-1. The mean gene expression for VEGFR-1 by day 7
at the LV-shRNA-VEGF-A-transduced vessels was signifi-
cantly lower than the control group (0.69±0.06 vs.
1.03±0.06, respectively, average reduction: 34%, Po0.001,
Figure 5c). By days 14 and 28, there was no difference
between the two groups (P¼NS).
VEGF-A silencing is associated with decreased mRNA levels
and immunostaining for HIF-1a
Because increased expression of HIF-1a has been observed in
animal models of hemodialysis graft failure and in clinical
specimens from patients with chronic graft failure, we
determined the expression levels for HIF-1a in outflow vein
sections transduced with either LV-shRNA-VEGF-A or
control shRNA. The mean gene expression of HIF-1a
(Figure 6a) at the LV-shRNA-VEGF-A-transduced vessels
was significantly lower than the control vessels by day 7
(1.54±0.11 vs. 2.1±0.17, respectively, average reduction:
27%, Po0.001) and day 14 (0.64±0.1 vs. 1.04±0.06,
respectively, average reduction: 39%, Po0.01).
We next determined the expression of HIF-1a by
immunostaining (Figure 6b). The average HIF-1a index
(number of HIF-1a-positive cells (brown)/total number of
cells100) of LV-shRNA-VEGF-A-transduced vessels when
compared with controls at day 14 (35.3±3.4 vs. 63.1±6.6,
respectively, average reduction: 44%, Po0.001, Figure 6b)
and day 21 (52.9±2.5 vs. 74.2±4.5, respectively, average
reduction: 29%, Po0.01). There was no difference by day 28
in the LV-shRNA-VEGF-A-transduced vessels when com-
pared with controls. In the Avastin-treated vessels, when
compared with controls, there was no difference in the
HIF-1a index at day 14 or day 28.
VEGF-A silencing in hypoxic fibroblasts reduces a-SMA
production at 24 and 72h
Previous studies have demonstrated that HIF-1a gene
expression is increased in failed hemodialysis graft specimens
removed from patients and in animal models of graft failure,
and other studies indicate that hypoxia can cause an increase
in fibroblast to myofibroblast differentiation.11,24,27–29 To
investigate this possibility, we determined whether reducing
VEGF-A gene expression in fibroblasts and then subjecting
them to hypoxia would cause a decrease in a-SMA
production. Murine AKR-2B cells transduced with either
LV-shRNA-VEGF-A (LV) or control shRNA-VEGF-A (C)
were subjected to 24 or 72 h of hypoxia. Expression of a-SMA
in the cell lysate was determined using western blot analysis.
Our results indicate a significant reduction in a-SMA
production at 24 h (17.7±1.5 vs. 45.9±4.6, LV-shRNA-
VEGF-A vs. control shRNA, respectively, average reduction:
61%, Po0.0001) and 72 h (17±3 vs. 66.3±9.2, LV-shRNA-
VEGF-A vs. control shRNA, respectively, average reduction:
74%, Po0.0001) of hypoxia when compared with controls
(Figure 7a). Confocal microscopy for a-SMA staining
performed on AKR-2B cells transduced with either LV-
shRNA-VEGF-A or control shRNA that had been subjected
to 24 or 72 h of hypoxia demonstrated similar results
(Figure 7b). Semiquantitative analysis for cells staining
positive for a-SMA (red) demonstrated a significant decrease
in the intensity of the a-SMA staining in the LV-shRNA-
VEGF-A-transduced cells when compared with controls at
24 h (132±5.8 vs. 179±3.4, respectively, average reduction:
27%, Po0.0001) and 72 h (18.7±9.42 vs. 100±9.5, respec-
tively, average reduction: 71%, Po0.0001, Figure 7c).
VEGF-A silencing in hypoxic fibroblasts reduces proliferation
and invasion
We next determined whether reducing VEGF-A gene
expression in fibroblasts and subsequently subjecting them
to hypoxia would decrease the proliferative potential
(thymidine incorporation assay) of fibroblasts when com-
pared with controls. Murine AKR-2B cells transduced with
either LV-shRNA-VEGF-A or control shRNA were subjected
to normoxia and hypoxia, and proliferation assay was
performed. This demonstrated a significant reduction in
LV-shRNA-VEGF-A-transduced cells when compared with
controls for normoxia at 48 h (85,552±5428 vs. 50,498±
3346, control shRNA vs. LV-shRNA-VEGF-A, respecti-
vely, average reduction: 41%, Po0.05, Figure 7d), with
significant reduction in hypoxia at 48 h (75,658±2915
vs. 50,243±1851, control shRNA vs. LV-shRNA-VEGF-A,
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respectively, average reduction: 34%, Po0.0001) and
72 h (110,250±1843 vs. 85,895±1492, control shRNA vs.
LV-shRNA-VEGF-A, respectively, average reduction: 22%,
Po0.0001).
As the proliferative ability of these cells was reduced, we
determined whether the invasive capacity of these cells was
reduced under the same conditions. Murine AKR-2B cells
transduced with either LV-shRNA-VEGF-A or control shRNA
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were subjected to normoxia and hypoxia, and a matrigel
invasion assay was performed. This demonstrated a sig-
nificant reduction in the invasive potential of LV-shRNA-
VEGF-A-transduced cells when compared with control
(normoxia: 600±10 vs. 400±10, control shRNA vs. LV-
shRNA-VEGF-A, respectively, average reduction: 33%,
Po0.05; hypoxia: 1400±10 vs. 400±10, control shRNA vs.
LV-shRNA-VEGF-A, respectively, average decrease: 350%,
Po0.0001, Figure 7e and f).
VEGF-A silencing in hypoxic fibroblasts decreases MMP-2
activity and increases caspase 3 activity
Because there was a decrease in proliferation and invasion in
cells transduced with LV-shRNA-VEGF-A, we determined
whether there was a decrease in MMP-2 expression using
zymography. We observed a significant decrease in the pro
MMP-2 (122±5.4 vs. 180±11, LV-shRNA-VEGF-A vs.
control shRNA, respectively, average reduction: 33%,
Po0.05) and active MMP-2 activity (103±24 vs. 171±28,
LV-shRNA-VEGF-A vs. control shRNA, respectively, average
reduction: 33%, Po0.05) at 24 h, with no difference by 72 h
(P¼NS, Figure 7g).
As VEGF-A is involved in cellular homeostasis, we
determined whether reducing VEGF-A expression would
result in an increase in caspase 3 activity (Figure 7h). We
observed a significant increase in caspase 3 activity in
LV-shRNA-VEGF-A-transduced cells when compared with
controls at 24 h (405,725±1013 vs. 292,723±558, respec-
tively, average increase: 160%, Po0.0001) and 72 h
(254,277±5870 vs. 137,980±2810, respectively, average
increase: 184%, Po0.0001) of hypoxia.
DISCUSSION
It is estimated that the number of patients with end-stage
renal disease who use hemodialysis as the preferred mode of
therapy will double in the next decade.1 For patients to
receive adequate hemodialysis, a well-functioning vascular
access is needed. The ‘Achilles heel’ of hemodialysis AVF or
grafts is stenosis formation caused by VNH that typically
occurs in the proximal outflow vein.6 Recent studies have
shown that 1-year primary patency of an AVF is 61% and that
the 6-month patency rates after angioplasty of venous
stenosis range from 0 to 23%.30,31 The mechanisms under-
lying the formation of VNH associated with hemodialysis
AVF or graft failure remain poorly understood.
VEGF-A is a multifunctional cytokine that has been
shown to be involved in cell proliferation, migration, and cell
death.25 Previous studies from our laboratory using
experimental animal models of VNH formation in hemo-
dialysis AVF or graft failure have demonstrated that there is
increased expression of VEGF-A and VEGFR-1 at the venous
stenosis when compared with the control vein (Po0.05).11–13
Increased expression of VEGF-A has been localized to the
adventitia and neointima in samples removed from patients
with failed hemodialysis vascular access.6 A recent study from
our laboratory demonstrated that simvastatin treatment
before the placement of AVF in a murine model of chronic
kidney disease reduced VNH formation by decreasing
VEGF-A and MMP-9 expression.10 In this study, we
targeted the adventitia using LV-shRNA-VEGF-A to reduce
VEGF-A gene expression, which resulted in a significant
increase in luminal vessel area, significant decrease in the
media/adventitia area, and a decrease in collagen expression.
We further observed similar results when we used systemic
delivery of Avastin. In both forms of therapy, a significant
reduction in VEGF-A staining was observed as well.
The result of silencing VEGF-A had two very important
effects. First, VEGF-A is needed for cell survival, and in this
study the decrease in VEGF-A resulted in increased cell death,
as demonstrated by increased caspase 3 activity and TUNEL
staining. Furthermore, we observed a decrease in cells
staining positive for a-SMA with a decrease in VEGFR-1
expression. VEGFR-1 is needed for cell proliferation and
migration, and a recent study showed that it might influence
cell death of smooth muscle cells.16 These results are
consistent with reports in animal models of arterial stenosis
that showed that blockade of VEGF-A using soluble
VEGFR-1 reduces intimal hyperplasia by blocking
Figure 7 | There is decreased proliferation, invasion, a-smooth muscle actin (a-SMA), and matrix metalloproteinase 2 (MMP-2)
expression with increased caspase 3 activities in the lentivirus (LV)–small hairpin RNA (shRNA)–vascular endothelial growth factor-A
(VEGF-A)–transduced cells subjected to hypoxia. Western blot for a-SMA after transduction LV-shRNA-VEGF-A (LV) and scrambled shRNA-
VEGF-A (C) in AKR-2B fibroblasts subjected to hypoxia at 24 and 72 h. A typical western blot is shown in the upper panel and the pooled data in
the lower panel (a). This demonstrates a significant reduction in the mean a-SMA expression in the LV-transduced cells when compared with C
cells at 24 (Po0.0001) and 72 h (Po0.0001). (b) Staining for a-SMA (red positive cells) at 24 and 72 h. (c) Pooled data for the average intensity of
cells staining positive for a-SMA, demonstrating a significant decrease in the LV-transduced cells when compared with C cells at both 24 and
72 h (both Po0.001). (d) Pooled data for proliferation using the thymidine incorporation assay for the LV-transduced cells when compared with
C cells, showing a significant decrease in proliferation for the normoxic groups at 48 and 72 h (Po0.0001) and for 24 (Po0.05), 48, and 72 h
(Po0.0001) of hypoxia. (e) Invasion assay for LV-transduced cells when compared with C cells for normoxia and hypoxia. (f) Pooled data for
invasion of the LV-transduced cells when compared with C cells, showing a significant decrease in both the normoxic (Po0.0001) and hypoxic
groups (Po0.0001). (g) Upper panel is a representative zymogram of LV-transduced cells when compared with C cells subjected to hypoxia at
24 and 72 h, and the lower panel shows pooled data demonstrating a significant reduction in both pro- and active-MMP-2 activity at 24 h for
LV-transduced cells when compared with C cells (Po0.05). (h) Pooled caspase 3 activity in LV-transduced cells when compared with C cells
subjected to hypoxia at 24 and 72 h, showing a significant increase in the mean caspase 3 activity in the LV-transduced cells when compared
with C cells at 24 and 72 h (both Po0.0001). (c) Each bar shows mean±s.e.m. of 3–6 different experiments per group. Two-way analysis of
variance (ANOVA) followed by Student’s t-test with post hoc Bonferroni’s correction was performed. Significant difference from control value is
indicated by *Po0.05, **Po0.01, or #Po0.001.
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recruitment of monocytes.21,22 In contrast, increased
expression of VEGFR-1 has been associated with increased
proliferation of mesenchymal cells such as vascular smooth
muscle and allied synthetic phenotypes.19
The second important effect of reducing mRNA for
VEGF-Awas a decrease in cellular proliferation and reduction
of Ki-67 staining in both LV-shRNA-VEGF-A-transduced and
Avastin-treated vessels when compared with controls. This
reduction in cellular proliferation was associated with a
reduction of several important genes responsible for cellular
migration including MMP-2 and MMP-9. In patients with
failed vascular access, as well as in experimental animal
models of hemodialysis AVF or graft failure, increased
expression of MMP-2 with adventitial localization of MMP-2
at the venous stenosis formation has been observed.11–13
These results are consistent with other studies that have
shown MMP inhibition in a rat and porcine model of
arteriovenous hemodialysis graft failure model has been
shown to reduce VNH formation.32,33
Adventitial delivery of LV-shRNA-VEGF-A demonstrated
a ‘top-down’ effect by showing that silencing mRNA
expression for VEGF-A was localized to the adventitia and
media at day 3 and the whole vessel wall by day 7 after
transduction. The temporal and spatial localization of
silencing VEGF-A corresponds with previous studies that
have demonstrated that adventitial fibroblasts and medial
cells can contribute to VNH formation.7–9 In addition,
adventitial remodeling has been observed to occur in stenosis
associated with arterial injury and lately and that associated
with hemodialysis graft failure.7–9 We observed a significant
reduction in the average area of the media and adventitia.
Taken collectively, these findings lead us to believe that
adventitial and medial remodeling is an important
contributor to the positive vascular remodeling that was
observed.
Hypoxic injury is known to accelerate conversion of
fibroblast to myofibroblasts (a-SMA-positive cells), and
increased HIF-1a has been observed in animal models
and in clinical specimens of AVF or graft failure.11,24,27–29
VEGF-A-mediated activation of fibroblasts to myofibroblast
phenotype is often accompanied by the activation of
matrix regulatory signaling moieties including MMP-2 and
Table 2 | PCR primers used in this study
Gene Sequence
Amplicon
length Cycles
HIF-1a 50-AGTGATGAAAGAATTACT-30 (sense) 2759 35
50-AATAATACCACTTACAACA-30 (antisense)
VEGF-A 50-ATGAAGTGATCAAGTTCATGG-30 (sense) 360 35
50-GGATCTTGGACAAACAAATGC-30 (anti-
sense)
VEGFR-1 50-TTTCCATTTGATACTCTTAC-30 (sense) 310 35
50-TCTTAGTTGCTTTACCAGGG-30 (antisense)
MMP-2 50-AGATCTTCTTCTTCAAGGACCGGTT-30
(sense)
225 35
50-GGCTGGTCAGTGGCTTGGGGTA-30 (anti-
sense)
MMP-9 50-GTTTTTGATGCTATTGCTGAGATCCA-30
(sense)
208 35
50-CCCACATTTGACGTCCAGAGAAGAA-30
(antisense)
18S 50-AGCTAGGAATAATGGAATAG-30 (sense) 150
50-AATCAAGAACGAAAGTCGGAG-30 (anti-
sense)
Abbreviations: HIF-1a, hypoxia-inducible factor-1a; MMP-2, matrix metalloproteinase
2; MMP-9, matrix metalloproteinase 9; VEGF-A, vascular endothelial growth factor-A;
VEGFR-1, vascular endothelial growth factor receptor 1.
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Figure 8 | Cartoon of proposed mechanism. Schematic showing
(a) normal vein, (b) vein after arteriovenous fistula (AVF) placement,
and (c) outflow vein after fistula placement with lentivirus (LV)–small
hairpin RNA (shRNA)–vascular endothelial growth factor-A (VEGF-A)
silencing and its different mechanisms. HIF-1a, hypoxia-inducible
factor-1a.
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MMP-9.34 Fibroblasts transduced with either LV-shRNA-
VEGF-A and subjected to hypoxia had a significant decrease
in a-SMA production, decreased invasion, proliferation,
MMP-2 activity, and an increase in caspase 3, offering a
potential cellular target for the in vivo observations. We
demonstrated that mRNA for HIF-1a in the outflow vein
vessels of the LV-shRNA-VEGF-A-transduced vessels was
significantly lower than control vessels, which was confirmed
with HIF-1a staining. In Avastin-treated vessels, we observed
no difference in HIF-1a index at either time point.
In vivo, we observed a significant reduction in both mRNA
and staining for HIF-1a in LV-shRNA-VEGF-A-transduced
vessels when compared with controls. We speculate that the
paradoxical reduction in HIF-1a associated with inhibition
of VEGF may be related to the decrease in metabolic demand
for oxygen secondary to a reduction in proliferation,
migration, and cell death. Taken together, these results
suggest that anti-VEGF-A therapy at the time of fistula
placement results in positive vascular remodeling in AVFs
because of multiple mechanisms that were mentioned.
Previous experimental models to study hemodialysis AVF
or graft failure have used animals with normal kidney
function. A recent study demonstrated that animal models
with abnormal kidney function have increased VNH
formation when compared with animals with normal kidney
function.35 Furthermore, increased expression of VEGF-A,
MMPs, and other important proteins has been found to be
elevated in patients on hemodialysis and therefore would be
consistent with the data obtained in our animal model.36–38
One limitation of this study is that cells such as
lymphocytes and macrophages may also have been trans-
duced with LV-shRNA-VEGF-A and may also be contributing
in part to the observed effects of positive vascular remodeling
besides the fibroblast. Another limitation is the choice of
mouse strain used to perform the remnant kidney model. It
is well known that C57BL/6 mice are resistant to glomerulo-
sclerosis, whereas other animals such as the BALB/c are more
prone.39,40 These genetic differences may influence the
outcomes observed in this study. The fistulas were placed
in central veins, and these fistulas may behave differently than
those placed in peripheral veins. We used Avastin, which is a
humanized antibody to VEGF-A, and there are reports that it
may weakly inhibit murine VEGF-A.41
In conclusion, our central hypothesis is that VNH
formation occurs in part because of local vessel hypoxia
caused by surgical trauma to the vasa vasorum supplying the
outflow vein at the time of AVF placement (Supplementary
Figure S4 online). This hypoxia in turn leads to an increase in
gene expression of VEGF-A, MMP-2, and MMP-9, resulting
in the activation of adventitial fibroblasts that undergo
conversion to myofibroblasts with increased proliferative and
migratory capacity, thereby resulting in VNH forma-
tion3,7,11,19,26 (Figure 8b). The normal vein is shown for
comparison in Figure 8a. This study demonstrates that
adventitial delivery of LV-shRNA-VEGF-A decreases the
expression of several important promigratory cytokines such
as VEGFR-1, MMP-2, and MMP-9 (Figure 8c). The net result
is an overall decrease in cell proliferation, decrease in a-SMA-
positive cells, with increased apoptosis resulting in positive
vascular remodeling, decreased media/adventitia area with
decreased constrictive remodeling. However, a significant
decrease in the average area of the neointima was not
observed. The results of these findings were extended to
Avastin, which demonstrated similar findings. The clinical
significance of this study is that it provides rationale for using
anti-VEGF-A therapies at the time of fistula creation to
reduce VNH formation.
MATERIALS AND METHODS
Experimental animals
Appropriate Institutional Animal Care and Use Committee approval
was obtained before performing any procedures. The housing and
handling of the animals was performed in accordance with the
Public Health Service Policy on Humane Care and Use of
Laboratory Animals revised in 2000.42 Animals were housed at
22 1C temperature, 41% relative humidity, and 12-/12-h light/dark
cycles. Animals were allowed access to water and food ad libitum.
Anesthesia was achieved with intraperitoneal injection of a mixture
of ketamine hydrochloride (0.20mg/g) and xylazine (0.02mg/g) and
maintained with intraperitoneal pentobarbital (20–40mg/kg). A
total of 204 male C57BL/6 mice (Jackson Laboratories, Bar Harbor,
ME) weighing 25–30 g were used for this study as depicted. One
normal kidney function mouse was used for micro-computed
tomography analysis. Chronic renal insufficiency was created by
surgical removal of the right kidney accompanied by ligation of the
arterial blood supply to the upper pole of the left kidney, as
described previously.14 At 4 weeks after nephrectomy, connecting
the right carotid artery to the ipsilateral jugular vein created an
AVF.14,23 Five million PFUs of either LV-shRNA-VEGF-A or
scrambled-shRNA-VEGF-A (control shRNA, nontargeting empty
vector) in 5 ml of PBS were injected using a 30-guage needle into the
adventitia of the proximal outflow vein at the time of AVF creation
at the time of fistula creation.43 In this animal model, venous
stenosis forms reproducibly at this location. Animals were killed at
days 3, 7, 14, 21, and 28 following AV fistula placement. RT-PCR,
protein, and histologic analyses were obtained. Serum BUN and
creatinine were measured by removing blood from the tail vein at
baseline (before nephrectomy), at AVF creation, and at the time of
killing. In a separate group of animals, intraperitoneal Avastin
(5mg/kg) or isotype-matched IgG was given every other day 1 week
before fistula placement and continued up to the time of killing at
either day 14 or day 28. Specimens were removed for
histomorphometric analysis only.
Vector constructs
The shRNA for VEGF-A was obtained from Open Bio-
systems (Huntsville, AL; (www.openbiosystems.com, RMM4534-
NM_001025250), and the lentivirus was prepared according to the
manufacturer’s protocol.
Tissue harvesting
At the time of killing, all mice were anesthetized as described
previously, and the fistula was dissected free of the surrounding
tissue. Animals were killed by CO2 asphyxiation, and the outflow
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veins were harvested for RT-PCR, histologic, or protein analyses. For
histologic analysis, all vessels were perfusion-fixed before removal.
Cell culture
To determine the efficacy and efficiency of lentiviral silencing on
VEGF-A expression, murine fibroblast (AKR-2B) cells were
transduced with either LV-shRNA-VEGF-A or scrambled-shRNA-
VEGF-A, and the expression was analyzed using RT-PCR or western
blotting, as described previously.10
Hypoxia chamber
AKR-2B transduced with LV-shRNA-VEGF-A or control shRNA
were made hypoxic for 24 or 72 h, as previously described.10,27
RNA isolation
The tissue was stored in RNA-stabilizing reagent (Qiagen,
Gaithersburg, MD) as per the manufacturer’s guidelines. To isolate
the RNA, the specimens were homogenized and total RNA was
isolated using the RNeasy mini kit (Qiagen).14,23
RT-PCR analysis
Expression for the gene of interest was determined using RT-PCR
analysis, as described previously.23,10 Primers used are shown in
Table 2.
In situ hybridization for VEGF-A
In situ hybridization for VEGF-A was performed as described
elsewhere.44 Briefly, the digoxigenin-labeled complementary RNA
probe was made with plasmid pBS-164-VEGF (gift from Andreas
Nagy, Toronto, Canada) using digoxigenin RNA labeling kit with T7
RNA polymerase for antisense (complementary to VEGF mRNA)
probe and T3 RNA polymerase for sense (control) probe (Roche
Applied Science, Indianapolis, IN). The probe hybridization was
performed as per guidelines from Roche Applied Science. The probe
hybridization was visualized using anti-digoxigenin-alkaline phos-
phatase antibody and NBT-BCIP solution as substrate (Roche
Applied Science).
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
zymography for MMP-2 and MMP-9
MMP-2 and MMP-9 protein activities were determined using
zymographic analysis. This was performed on homogenates from
cultured cells or outflow veins transduced with either LV-shRNA-
VEGF-A or control shRNA as described previously.7,13
Western blot of a-SMA
We assessed the differentiation of fibroblasts to myofibroblasts by
performing western blot analysis for a-SMA. The cultured cells were
processed for western blot analysis using rabbit polyclonal antibody,
as described previously.13
Caspase 3 activity
Apoptosis was assessed using enzyme-linked immunosorbent assay
for caspase 3. Cellular protein was extracted from cultured cells and
mouse tissue, as described previously. The enzymatic activity of
caspase 3 was assessed by Caspase Glo assay (G811C, Promega,
Madison, WI) as described earlier.10
Proliferation assay
A total of 20,000 AKR-2B cells transduced with LV-shRNA-VEGF-A
or control shRNA were seeded in 24-well plates and cultured for 24,
48, and 72 h in Dulbecco’s modified Eagle’s medium. After 20, 44,
and 68 h, 1mCi of [3H]-thymidine was added to each well, and 4 h
later cells were washed with chilled PBS, fixed with 100% cold meth-
anol, and collected for measurement of trichloroacetic acid–
precipitable radioactivity. Experiments were repeated at least three
times for each time point.
Invasion and cell migration assay
A total of 5000 AKR-2B cells transduced with LV-shRNA-VEGF-A or
control shRNA were seeded in 8 mm Transwells (Corning Life
Sciences, Tewksbury, MA) that were precoated with low growth
factor matrigel in a serum-free medium. The complete medium was
supplemented under the Transwell and incubated for 6 h at 37 1C.
After 6 h, Transwells were washed with PBS and fixed with
paraformaldehyde (4% v/v). Finally, Transwells were stained with
bromophenol (0.1%) solution. The cells from the upper well were
removed with cotton-tip applicators. The cells from the bottom well
were counted for analysis.
Tissue processing and immunohistochemistry
Each outflow vein from each animal was embedded in paraffin
lengthwise so that the sections would be orthogonal to the long axis
of the vessel, as described previously.10 Typically, 80–120 4-mm
sections were obtained, and the cuff used to make the anastomosis
could be visualized. Every 40-mm, 2–4 sections were stained with
hematoxylin and eosin, Ki-67, a-SMA, CD31, HIF-1a, and VEGF-A
were performed on paraffin-embedded sections from the outflow
vein after transduction with either LV-shRNA-VEGF-A or control
shRNA or Avastin with control using the EnVision (DAKO,
Carpinteria, CA) method with a heat-induced antigen retrieval
step.7,13 The following antibodies were used: mouse monoclonal
antibody Ki-67 (DAKO, 1:400), CD31 (Abcam, Cambridge, MA;
1:400), rabbit polyclonal antibody to mouse for VEGF-A (Abcam,
1:600), rabbit polyclonal antibody to mouse for HIF-1a (Novus
Biologicals, Littleton, CO, 1:200), or rabbit polyclonal antibody to
mouse for a-SMA (Abcam, 1:400). IgG antibody staining was
performed to serve as controls.
TUNEL staining
TUNEL staining10 was performed on paraffin-embedded sections
from the outflow vein after transduction with either LV-shRNA-
VEGF-A or control shRNA or Avastin or control vessels, as specified
by the manufacturer (DeadEnd Colorimetric tunnel assay system,
G7360, Promega). Negative control is shown where the recombinant
terminal deoxynucleotidyl transferase enzyme was omitted.
Picrosirius red staining
Picrosirius red staining was performed on unstained sections from
LV-shRNA-VEGF-A and scrambled shRNA VEGF-A or Avastin-
treated or control vessels at different time points, as described
previously.10
Morphometry and image analysis
Paraffin-embedded sections (4 mm) immunostained for hematoxylin
and eosin stains were viewed with an Axioplan 2 Microscope (Zeiss,
Oberkochen, Germany) equipped with a Neo-Fluor20/0.50
objective and digitized to capture a minimum of 30903900 pixels
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using a Axiocam camera (Zeiss).7,10,13 Images covering one entire
cross-section from each section of the outflow vein transduced with
either LV-shRNA-VEGF-A or control shRNA or Avastin treated with
control vessels were acquired and analyzed using KS 400 Image
Analysis software (Zeiss). For morphometric analysis used to
quantify the lumen vessel area and wall vessel area, we used 6–10
4-mm paraffin-embedded sections removed from the outflow vein
for each animal at each time point. Sections were subsequently
viewed with an Axioplan 2 Microscope (Zeiss) equipped with a
Neo-Fluor20/0.50 objective and digitized to capture at least
10301300 pixels and cell density determined along with the vessel
wall and luminal vessel areas. The area was measured by tracing the
vessel wall using an automated program.13 Ki-67-positive (brown),
a-SMA-positive (brown), TUNEL-positive (brown), HIF-1a-
positive (brown), or in situ hybridization–positive (brown) cells
were highlighted, in turn, by selecting the appropriate red–green–
blue color intensity range and then counted. The Ki67, a-SMA,
TUNEL, and HIF-1a indices were calculated by counting the
number of brown positive cells/total number of cells100. This was
performed manually. This was repeated twice to ensure that
intraobserver variability was o10%.
Micro-computed tomography analysis for the vasa vasorum
of the jugular vein
Three-dimensional microscopic computed tomography was per-
formed to determine the presence of the vasa vasorum in the jugular
vein of a C57Bl/6 mouse, as previously described.45 A representative
figure is provided in Supplementary Figure S4 online.
Statistical methods
Data are expressed as mean±s.e.m. Multiple comparisons were
performed with two-way analysis of variance followed by Student’s
t-test with post hoc Bonferroni’s correction. We used Kaplan–Meier
survival model to assess for differences in patency between groups. A
log-rank test was performed. Significant difference from control
value was indicated by *Po0.05, **Po0.001, or #Po0.0001 for
in vitro experiments and *Po0.01, **Po0.001, or #Po0.0001 for
in vivo experiments. For comparison of gene expression for VEGF-A
in Avastin-treated vessels compared with controls only, a paired
Student’s t-test was performed with significance at Po0.05. JMP
version 9 (SAS Institute, Cary, NC) was used for statistical analyses.
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